| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 26.77B | 27.10B | 28.33B | 36.25B | 25.96B | 17.14B |
| Gross Profit | 8.99B | 9.65B | 9.74B | 17.05B | 7.60B | 441.00M |
| EBITDA | 12.15B | 12.72B | 14.54B | 22.16B | 13.89B | -6.14B |
| Net Income | 2.07B | 3.04B | 4.67B | 13.22B | 2.31B | -14.83B |
Balance Sheet | ||||||
| Total Assets | 83.47B | 85.44B | 74.01B | 72.61B | 75.04B | 80.06B |
| Cash, Cash Equivalents and Short-Term Investments | 2.16B | 2.13B | 1.43B | 984.00M | 2.76B | 2.01B |
| Total Debt | 22.88B | 27.10B | 20.91B | 20.77B | 30.39B | 37.30B |
| Total Liabilities | 46.71B | 50.97B | 43.66B | 42.52B | 54.71B | 61.49B |
| Stockholders Equity | 36.26B | 34.16B | 30.25B | 30.09B | 20.33B | 18.57B |
Cash Flow | ||||||
| Free Cash Flow | 3.80B | 4.42B | 6.06B | 12.46B | 7.56B | 1.42B |
| Operating Cash Flow | 11.25B | 11.44B | 12.31B | 16.81B | 10.43B | 3.96B |
| Investing Cash Flow | -5.78B | -14.59B | -6.98B | -4.87B | -1.25B | -819.00M |
| Financing Cash Flow | -5.07B | 3.84B | -4.89B | -13.71B | -8.57B | -4.52B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $45.59B | 11.06 | 10.92% | 2.70% | 60.29% | -17.62% | |
79 Outperform | $24.75B | 9.28 | 18.35% | 2.64% | 11.14% | -21.32% | |
78 Outperform | $58.92B | 10.81 | 18.48% | 3.79% | -5.15% | -19.06% | |
74 Outperform | $32.45B | 11.16 | 8.33% | 6.85% | 15.31% | 58.83% | |
73 Outperform | $20.95B | 12.70 | 11.86% | 3.39% | 26.13% | 31.42% | |
66 Neutral | $43.89B | 32.42 | 5.82% | 2.39% | -2.48% | -65.26% | |
65 Neutral | $15.17B | 7.61 | 4.09% | 5.20% | 3.87% | -62.32% |
On January 2, 2026, Occidental completed the $9.7 billion all-cash sale of its chemical business, OxyChem, to Berkshire Hathaway, finalizing a divestiture first agreed in October 2025. The transaction is intended to accelerate Occidental’s strategy to strengthen its balance sheet and sharpen its focus on its higher-return oil and gas portfolio, while the company retains OxyChem’s legacy tort claims and certain environmental liabilities in a separate subsidiary that will continue funding and managing long-term remediation activities, a structure that preserves the operational value of the assets for the buyer while keeping historical risk obligations with Occidental.
The most recent analyst rating on (OXY) stock is a Hold with a $46.00 price target. To see the full list of analyst forecasts on Occidental Petroleum stock, see the OXY Stock Forecast page.